ArticleMolecular and cellular endocrinology2018
Dysregulation of Δ
Article in Molecular and cellular endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone.The Journal of clinical endocrinology and metabolism · 2021Trial
- Bile acids as a "new hormone" in aging-related liver disease.Life medicine · 2026Review
- The Spatial Transcriptional Activity of Hepatic TCF7L2 Regulates Zonated Metabolic Pathways that Contribute to Liver Fibrosis.Nature communications · 2025Article
- Shenmai injection revives cardiac function in rats with hypertensive heart failure: involvement of microbial-host co-metabolism.BMC complementary medicine and therapies · 2025Article
- AKR1D1 knockout mice develop a sex-dependent metabolic phenotype.The Journal of endocrinology · 2022Article
- Genome-wide association study reveals candidate genes relevant to body weight in female turkeys (Meleagris gallopavo).PloS one · 2022Article
- Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.Nature reviews. Gastroenterology & hepatology · 2021Review
- Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease.Liver research (Beijing, China) · 2021Review
- Differential activity and expression of human 5β-reductase (AKR1D1) splice variants.Journal of molecular endocrinology · 2021Article
- Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2021Article
- Glucocorticoids regulate AKR1D1 activity in human liver in vitro and in vivo.The Journal of endocrinology · 2020Article
- Unraveling genomic associations with feed efficiency and body weight traits in chickens through an integrative approach.BMC genetics · 2019Article
- AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease.Metabolism: clinical and experimental · 2019Article
- AKR1D1 regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells.The Journal of steroid biochemistry and molecular biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Aldo-keto reductase family 1 member D1 (AKR1D1) is a Δ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.